(Q24309649)

0 references

Nelofer Syed

0 references

Ornella Garrone

0 references

Milena Gasco

0 references

Andrew N J Tutt

0 references

Tim Crook

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

0 references

language of work or name

English

0 references

publication date

February 2008

0 references

0 references

0 references

0 references

91-104

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

The nuclear receptor superfamily: the second decade

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Predictors of response to aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

A new estrogen receptor antagonist--an overview of available data

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Minimizing the risk of reporting false positives in large-scale RNAi screens

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Utilizing RNA interference to enhance cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

TRANSFAC: a database on transcription factors and their DNA binding sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

1 reference

7 January 2021

Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021

Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2008.01.001

7 January 2021